160 related articles for article (PubMed ID: 25914330)
1. Identification of drug-induced toxicity biomarkers for treatment determination.
Lu TP; Chen JJ
Pharm Stat; 2015; 14(4):284-93. PubMed ID: 25914330
[TBL] [Abstract][Full Text] [Related]
2. An approach to identifying preclinical biomarkers of susceptibility to drug-induced toxicity.
Lin WJ; Chen JJ
Pharmacogenomics; 2011 Apr; 12(4):493-501. PubMed ID: 21521022
[TBL] [Abstract][Full Text] [Related]
3. Biomarker classifiers for identifying susceptible subpopulations for treatment decisions.
Lin WJ; Chen JJ
Pharmacogenomics; 2012 Jan; 13(2):147-57. PubMed ID: 22188363
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a statistical equivalence test applied to microarray data.
Qiu J; Cui X
J Biopharm Stat; 2010 Mar; 20(2):240-66. PubMed ID: 20309757
[TBL] [Abstract][Full Text] [Related]
5. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
6. Identifying drug active pathways from gene networks estimated by gene expression data.
Tamada Y; Imoto S; Tashiro K; Kuhara S; Miyano S
Genome Inform; 2005; 16(1):182-91. PubMed ID: 16362921
[TBL] [Abstract][Full Text] [Related]
7. Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data.
Gui J; Li H
Bioinformatics; 2005 Jul; 21(13):3001-8. PubMed ID: 15814556
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis method for discovering reliable biomarkers by integrating statistical and biological approaches: An application to liver toxicity.
Cho H; Kim H; Na D; Kim SY; Jo D; Lee D
Biochem Biophys Res Commun; 2016 Mar; 471(2):274-81. PubMed ID: 26820531
[TBL] [Abstract][Full Text] [Related]
9. Identification of partially linear structure in additive models with an application to gene expression prediction from sequences.
Lian H; Chen X; Yang JY
Biometrics; 2012 Jun; 68(2):437-45. PubMed ID: 21950383
[TBL] [Abstract][Full Text] [Related]
10. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
Roses AD
Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
[TBL] [Abstract][Full Text] [Related]
11. Sample size calculation through the incorporation of heteroscedasticity and dependence for a penalized t-statistic in microarray experiments.
Hirakawa A; Hamada C; Yoshimura I
J Biopharm Stat; 2012; 22(2):260-75. PubMed ID: 22251173
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional profiling to identify biomarkers of disease and drug response.
Mendrick DL
Pharmacogenomics; 2011 Feb; 12(2):235-49. PubMed ID: 21332316
[TBL] [Abstract][Full Text] [Related]
13. A GMM-IG framework for selecting genes as expression panel biomarkers.
Wang M; Chen JY
Artif Intell Med; 2010; 48(2-3):75-82. PubMed ID: 20004087
[TBL] [Abstract][Full Text] [Related]
14. Regularized ROC method for disease classification and biomarker selection with microarray data.
Ma S; Huang J
Bioinformatics; 2005 Dec; 21(24):4356-62. PubMed ID: 16234316
[TBL] [Abstract][Full Text] [Related]
15. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of adverse drug reactions.
Carr DF; Pirmohamed M
Exp Biol Med (Maywood); 2018 Feb; 243(3):291-299. PubMed ID: 28950720
[TBL] [Abstract][Full Text] [Related]
17. Strategies for power calculations in predictive biomarker studies in survival data.
Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
[TBL] [Abstract][Full Text] [Related]
18. A Novel "Maximizing Kappa" Approach for Assessing the Ability of a Diagnostic Marker and Its Optimal Cutoff Value.
Chang CH; Yang JT; Lee MH
J Biopharm Stat; 2015; 25(5):1005-19. PubMed ID: 24918528
[TBL] [Abstract][Full Text] [Related]
19. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: myocardial and infectious adverse reactions as application cases.
Wang K; Weng Z; Sun L; Sun J; Zhou SF; He L
Biochem Biophys Res Commun; 2015 Feb; 457(3):249-55. PubMed ID: 25576362
[TBL] [Abstract][Full Text] [Related]
20. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
Huber C; Benda N; Friede T
Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
